News PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.75 ^USD	+2.34%		+8.70%	-43.55%

Apr. 12	Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	MT
Mar. 27	PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Jefferies Starts PMV Pharmaceuticals With Buy Rating, $5 Price Target	Apr. 12	MT
PMV Pharmaceuticals Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220C-Positive Solid Tumors	Mar. 27	AQ
PMV Pharmaceuticals, Inc. Announces First Patient Dosed in Global Tumor-Agnostic Phase 2 PYNNACLE Trial for Rezatapopt in TP53 Y220c-Positive Solid Tumors	Mar. 27	CI
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s Cancer	Mar. 18	AQ
PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women's Cancer	Mar. 18	CI
North American Morning Briefing : Stock Futures -2-	Mar. 06	DJ
PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate Highlights	Feb. 29	AQ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
PMV Pharmaceuticals to Participate in the TD Cowen 44th Annual Health Care Conference	Feb. 26	AQ
PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash Runway	Jan. 18	AQ
PMV Pharmaceuticals, Inc. Announces Workforce Reduction of Approximately 30%	Jan. 18	CI
PMV Pharmaceuticals Names Michael Carulli as CFO; Phase 2 Trial of Tumor Treatment on Track	Jan. 05	MT
PMV Pharmaceuticals Strengthens Leadership with Key Appointments as Company Advances into Late-Stage Development	Jan. 05	AQ
PMV Pharmaceuticals, Inc. Announces Chief Financial Officer Changes	Jan. 05	CI
PMV Pharmaceuticals, Inc. Announces Executive Changes	Jan. 05	CI
Ladenburg Thalmann Initiates PMV Pharmaceuticals at Buy With $7 Price Target	Dec. 27	MT
PMV Pharmaceuticals, Inc.(NasdaqGS:PMVP) dropped from NASDAQ Biotechnology Index	Dec. 15	CI
PMV Pharmaceuticals Reports Third Quarter 2023 Financial Results and Corporate Highlights	Nov. 09	AQ
PMV Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
HC Wainwright Cuts Price Target on PMV Pharmaceuticals to $5 From $29, Maintains Buy Rating	23-10-16	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News PMV Pharmaceuticals, Inc.

Equities

PMVP

US69353Y1038

Summary

Filters